Study Details
A Study with ASP2151 in Subjects with Recurrent Episodes of Genital Herpes
This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).
Clinicaltrials.gov ID
The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
Astellas Study ID
The unique identification code given by the study sponsor.
15L-CL-101
EudraCT ID
The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).
N/A
Condition
Infections
Phase
These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.
Phase 2
Age
18 years - N/A
Sex
Female & Male
Product
N/A
Type
A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
Interventional
Trial Dates
Jun 2007 - Aug 2008
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment number
695
A Phase II, Dose-Finding Study with ASP2151 in Subjects with Recurrent Episodes of Genital HErpes
Study summary
Study documents
Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study with ASP2151 in Subjects with Recurrent Episodes of Genital Herpes? Contact us by filling our your information to the right and we’ll respond to you.